Enrolling by invitationEarly phase 1
COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO
Key facts
- Who runs it
- Dr ayesha wahid
- Where
- Lahore, PakistanSee the site
- Trial code
- Status
- Enrolling by invitation
- Phase
- Early phase 1
- People taking part
- 60 people, planned
- Started
- 1 May 2025
- Planned end
- 30 Aug 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tacrolimus
- Calcipotriol
- Record updated
- 24 June 2025
Who can take part
- Age
- 15 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Localized vitiligo Age 15 to 70years Body surface upto 20% Stable more than 3 months
Who cannot take part
- • Pregnant or lactating female patients; Skin malignancy or any other malignant skin condition; Photo induced or photo aggravated dermatosis like (SLE, photodermatitis, rosacea, psoriasis, pemphigus vulgaris) along with vitiligo; Prior history of allergy to tacrolimus or calcipotriol; Other form of treatment for vitiligo within at least 1 month
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 70 years old?
Where in Pakistan
- Lahore General HospitalLahore, PakistanNo longer taking part
About the trial
What the trial wants to find out
Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed
The 2 groups in the trial
- TacrolimusExisting treatment, for comparison
Patient of Limited vitiligo less than 20% BSA will be treated with topical tacrolimus and narrowband UVB
- CalcipotriolExisting treatment, for comparison
Calcipotriol is a vitamin D analogue that will act as immunomodulator
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Fit questions
- Built from NCT06880042, who can take part
- Record updated
- 24 June 2025